Association between reported statin use at baseline and institutionalisation and death, adjusted for continuous and quintiles of propensity scores (n=1497)
| Categorisation of statin use | Adjusted HR (95% CI)* | Adjusted HR (95% CI)† | ||
|---|---|---|---|---|
| Institutionalisation | Death | Institutionalisation | Death | |
| Statin exposure | ||||
| Non-users‡ | 1.00 | 1.00 | 1.00 | 1.00 |
| Users | 1.43 (0.87 to 2.34) | 0.82 (0.61 to 1.10) | 1.32 (0.81 to 2.15) | 0.81 (0.61 to 1.08) |
| Duration of statin use | ||||
| Non-users | 1.00 | 1.00 | 1.00 | 1.00 |
| 0–<4 | 1.77 (1.01 to 3.11) | 0.74 (0.52 to 1.06) | 1.65 (0.95 to 2.86) | 0.73 (0.51 to 1.04) |
| ≥4 | 1.15 (0.64 to 2.08) | 0.88 (0.64 to 1.22) | 1.07 (0.59 to 1.91) | 0.87 (0.64 to 1.20) |
| Standardised daily dose§ | ||||
| Non-users | 1.00 | 1.00 | 1.00 | 1.00 |
| Low | 1.17 (0.65 to 2.13) | 0.85 (0.61 to 1.19) | 1.10 (0.60 to 1.99) | 0.84 (0.60 to 1.17) |
| Medium | 1.73 (0.92 to 3.27) | 0.87 (0.60 to 1.28) | 1.57 (0.85 to 2.93) | 0.87 (0.60 to 1.27) |
| High | 1.71 (0.82 to 3.57) | 0.66 (0.41 to 1.07) | 1.56 (0.75 to 3.24) | 0.65 (0.41 to 1.05) |
*The HR estimated from Cox models, adjusted for continuous propensity score.
†The HR estimated from Cox models, adjusted for quintiles of propensity score.
‡Non-users, the reference group.
§Standardised daily dose was defined as follows: one unit of equivalent dose was based on a lipid-lowering effect of 10 mg of atorvastatin (fluvastatin 80 mg, lovastatin 40 mg, pravastatin 40 mg, simvastatin 20 mg, rosuvastatin 5 mg).18 ,19 Low dose was defined as <2 standardised unit, medium dose as 2–4 standardised unit and high dose as ≥4 standardised unit.